Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM14CQ
|
|||
| Drug Name |
HPN328
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
| Company |
Harpoon Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Delta-like protein 3 (DLL3) | Target Info | . | [2] |
| KEGG Pathway | Endocrine resistance | |||
| Notch signaling pathway | ||||
| Th1 and Th2 cell differentiation | ||||
| Pathways in cancer | ||||
| Breast cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04471727) Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Harpoon Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.